

January 24, 2025

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

The National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 541540, 890202

Scrip Code: SOLARA, SOLARAPP

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on January 24, 2025 and Submission of Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Nine months ended December 31, 2024 as per Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”).

We wish to inform that meeting of Board of Directors of Solara Active Pharma Sciences Limited (“Company”) held today (i.e., Friday, the January 24, 2025), the Directors has inter-alia:

- i. **Considered and Approved Unaudited Financial Results (Standalone and Consolidated)** of the Company for the Quarter and Nine months ended December 31, 2024, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which was reviewed by the Audit Committee. A copy of the unaudited financial results (standalone and consolidated) along with the Limited Review Report by the Auditors and press release is attached.

Please note that aforesaid Financial Results will also be available on the Company's website at <https://solara.co.in/investor-relations/financial-information>.

- ii. **Exploring potential demerger of the CRAMS and Polymers business into an independent listed entity.**

The Board of Directors had discussed a proposal to explore ‘demerger of the CRAMS and Polymers business into an independent listed entity’ and granted in-principle approval for the same. The rationale discussed was to enable differentiated and improved focus on this business.

The Board has authorised the Management to undertake preparatory steps required for the potential demerger including appointing of Valuers and other intermediaries for drawing up of the scheme of arrangement which will be placed before the Board.



Communication Address:

Solara Active Pharma Sciences Limited
2nd Floor, Admin Block
27, Vandaloor Kelambakkam Road,
Keelakottaiyur Village, Melakottaiyur (Post)
Chennai – 600 127, India
Tel: +91 44 43446700
Fax: +91 44 47406190
E-mail: investors@solara.co.in
www.solara.co.in

The Company will make appropriate disclosures in accordance with the SEBI Listing Regulations and other applicable laws, post consideration and approval of the matter by the Board.

The Board Meeting commenced at 12:00 pm and concluded at 2.15 pm.

We request you to take the same on record.

Thanking you,
Yours faithfully,

For Solara Active Pharma Sciences Limited

SUDDAPALLI
MURALIKRISHNA

Digitally signed by SUDDAPALLI
MURALIKRISHNA
Date: 2025.01.24 14:17:57 +05'30'

S. Murali Krishna
Company Secretary & Compliance Officer

Encl.: As above

Solara Active Pharma Sciences Limited - CIN: L24230MH2017PLC291636

REGD. OFF: 201, Devavrata, Sector 17, Vashi Navi Mumbai - 400703, India/ Tel: 91-22-2789 2924 / 2789 3199 / Fax: 91-22-2789 2942